Health Economics›Colorectal cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Colorectal cancer · 22 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trifluridine and tipiracil and Bevacizumab Variant #01	—	R 1 032 500	28d	4.6 mo	10.8 mo	6	R 6 195 003 PFS proxy	2
Trifluridine and tipiracil monotherapy Variant #01	—	R 1 013 418	28d	2.6 mo	7.8 mo	3	R 3 040 255 PFS proxy	6
Regorafenib monotherapy Variant #06	—	R 307 423	28d	—	9.3 mo	—	—	4
Pembrolizumab monotherapy Variant #01	MSI-H	R 286 955	14d	~16.5 mo	~77.5 mo	~36	~R 10 330 390 PFS proxy · indirect	3
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	6.6 mo	—	—	1
Ipilimumab and Nivolumab Variant #01 Partial	MSI-H	R 78 615	42d	—	~18.2 mo	—	—	2
Irinotecan and Cetuximab Variant #03	RAS	R 52 752	14d	2.0 mo	5.9 mo	5	R 263 760 PFS proxy	4
Cetuximab monotherapy Variant #04	RAS	R 29 164	7d	—	8.1 mo	—	—	3
Panitumumab monotherapy Variant #01	RAS	R 25 254	14d	1.8 mo	10.2 mo	4	R 101 017 PFS proxy	3
FOLFOX4 and Bevacizumab Variant #01	—	R 21 146	14d	—	12.9 mo	—	—	1
Adagrasib and Cetuximab Variant #02 Partial	KRAS	R 17 155	7d	—	—	—	—	—
FULV and Bevacizumab Variant #02	—	R 11 648	14d	—	—	—	—	—
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	—	~9	~R 19 974 PFS proxy · indirect	5
FOLFOX4 Variant #01	—	R 2 064	14d	4.8 mo	11.9 mo	11	R 22 700 PFS proxy	4
FOLFOX4 (L-Leucovorin) Variant #01 Partial	—	R 1 106	14d	—	11.9 mo	—	—	1
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	8.5 mo	—	—	—
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	10.9 mo	—	—	4
Fruquintinib monotherapy Variant #01 Partial	—	—	28d	—	8.4 mo	—	—	2
Best supportive care Partial	—	—	—	1.7 mo	4.6 mo	—	—	4
Placebo Partial	—	—	—	1.4 mo	6.3 mo	—	—	9
Nivolumab monotherapy Variant #01 Partial	MSI-H	—	14d	~1.8 mo	~10.9 mo	~4	—	6
Adagrasib monotherapy Variant #01 Partial	KRAS	—	28d	~5.5 mo	—	~6	—	1

22 of 22 regimens shown